Analysis and commentary from clinicians, researchers and patients across the field.
Medical cannabis patients are often framed as consumers chasing the next strain, but that overlooks how many navigate treatment, writes Dave Barton.
Dr Sue Clenton, Medical Director at Releaf Cannabis Clinic, shares her insight from the frontline of an emerging field of medicine.
Dr Sue Clenton, Consultant Oncologist and Medical Director at Releaf Cannabis Clinic, shares her insight from the front line of an emerging field of medicine.
In her bi-weekly series for Cannabis Health, Dr Sue Clenton, Consultant Oncologist and Medical Director at Releaf Cannabis Clinic, shares her insight from the front line of an emerging field […]
In her new bi-weekly series for Cannabis Health, Dr Sue Clenton, Consultant Oncologist and Medical Director at Releaf Cannabis Clinic, shares her insight from the front line of an emerging […]
In her new bi-weekly series for Cannabis Health, Dr Sue Clenton, Consultant Oncologist and Medical Director at Releaf Cannabis Clinic, shares her insight from the front line of an emerging […]
How one oncologist is helping redefine patient care and the future of integrated healthcare. Medical cannabis is starting to have a very different kind of conversation in the UK. From […]
James Smith, co-founder of 4C Labs, shares his recent experience using cannabis-based medicines after a hip replacement.
Words by Dr Sue Clenton, Medical Director, Releaf If we are serious about the future of medical cannabis in the UK, we must be equally serious about its clinical […]
Michael Sassano, CEO and founder of SOMAÍ Pharmaceuticals, explores the latest developments in Ukraine.
Almost six years since the law change, children still struggle to access a consistent supply of medicine in the UK, writes Matt Hughes, Medcan Family Foundation.
Michael Sassano CEO and founder of SOMAÍ Pharmaceuticals, explains how to find the right dose.
James Leavesley and Brady Green, head grower at Dalgety, discuss what insights the UK can glean from more advanced markets.
